Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?   

The PACIFIC study represents an important advancement for patients with unresectable, stage III NSCLC. The initial OS results were presented recently and demonstrated a significant improvement in survival for patients receiving durvalumab following chemoradiation. The median time has not been reach...

This is a highly controversial topic that frequently arises and I think there are multiple plausible interpretations of the PACIFIC data. I previously posted on this topic [see https://www.themednet.org/question/18570], but I generally do not offer durvalumab for these patients. I anticipate the LAU...